Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer (COL)

September 15, 2026 updated by: Centre Oscar Lambret

Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer

The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.

Study Overview

Detailed Description

Further informations will be provided by Centre Oscar Lambret.

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Angers, France, 49933
        • Centre Paul Papin
      • Brest, France, 29200
        • Centre Hospitalier Universitaire
      • Caen, France, 14046
        • Centre François Baclesse
      • Lille, France, 59020
        • Centre Oscar Lambret
      • Rennes, France, 35042
        • Centre Eugene Marquis
      • Rouen, France, 76031
        • CHU - Hopital Charles Nicolle

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a), histologically proven
  • Treated by exclusive concomitant radiochemotherapy
  • Written informed consent

Exclusion Criteria:

  • Presence of a second uncontrolled cancer
  • Metastatic carcinoma
  • Metastatic disease, except cervical lymphnodes... (M1a)
  • In situ carcinoma
  • Eso-gastric junction cancer (Siewert II ou III)
  • Inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Proteomic analysis by Protein-Chip Technology of Ciphergen and mass spectrometry
Time Frame: 15 weeks after the end of irradiation
15 weeks after the end of irradiation
Initial complete clinical response
Time Frame: 15 weeks after the end of irradiation
15 weeks after the end of irradiation

Secondary Outcome Measures

Outcome Measure
Time Frame
Prolonged clinical response at one year
Time Frame: One year after the end of irradiation
One year after the end of irradiation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: ADENIS Antoine, MD, PhD, Centre Oscar Lambret

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2007

Primary Completion (Actual)

September 1, 2011

Study Completion (Actual)

December 1, 2011

Study Registration Dates

First Submitted

May 29, 2009

First Submitted That Met QC Criteria

May 29, 2009

First Posted (Estimated)

June 1, 2009

Study Record Updates

Last Update Posted (Actual)

September 17, 2026

Last Update Submitted That Met QC Criteria

September 15, 2026

Last Verified

September 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe